Publications by authors named "P J Lestrade"
We investigated the prevalence of azole resistance of Aspergillus fumigatus isolates in the Netherlands by screening clinical A. fumigatus isolates for azole resistance during 2013-2018. We analyzed azole-resistant isolates phenotypically by in vitro susceptibility testing and for the presence of resistance mutations in the Cyp51A gene.
View Article and Find Full Text PDFArticle Synopsis
- Aspergillus fumigatus resistance to voriconazole, a common antifungal, poses a significant risk, particularly in hematology patients, with reported mortality rates ranging from 50% to 100%.
- A study on 129 culture-positive invasive aspergillosis cases found 20.2% were voriconazole-resistant, with most resistant strains having specific mutations.
- The research showed that non-ICU patients with voriconazole-resistant infections had a noticeably higher mortality rate at 12 weeks compared to those with susceptible infections, highlighting the urgency of addressing this resistance problem.
Background: Triazole resistance in Aspergillus fumigatus is widespread and threatens first-line triazole therapy in patients with Aspergillus diseases.
Objectives: To give an overview of the microbiology, epidemiology and clinical significance of triazole resistance in aspergillosis.
Sources: PubMed search for articles on resistance in Aspergillus species.
Background: Triazole resistance is an increasing problem in invasive aspergillosis (IA). Small case series show mortality rates of 50%-100% in patients infected with a triazole-resistant Aspergillus fumigatus, but a direct comparison with triazole-susceptible IA is lacking.
Methods: A 5-year retrospective cohort study (2011-2015) was conducted to compare mortality in patients with voriconazole-susceptible and voriconazole-resistant IA.
Objectives: To investigate the epidemiology and clinical relevance of triazole resistance among patients undergoing treatment for haematological malignancies who are at risk of invasive aspergillosis (IA).
Methods: This was a retrospective cohort study for which the records of consecutive patients given chemotherapy for AML or myelodysplastic syndrome (MDS) or who had received an allogeneic HSCT from 2006 to 2012 were reviewed for IA. Triazole resistance was detected by the VIPcheck™ screening method and confirmed by determining the MIC by EUCAST methodology.